Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy
Citations Over TimeTop 1% of 2015 papers
Abstract
Photodynamic therapy (PDT) kills cancer cells by converting tumour oxygen into reactive singlet oxygen ((1)O2) using a photosensitizer. However, pre-existing hypoxia in tumours and oxygen consumption during PDT can result in an inadequate oxygen supply, which in turn hampers photodynamic efficacy. Here to overcome this problem, we create oxygen self-enriching photodynamic therapy (Oxy-PDT) by loading a photosensitizer into perfluorocarbon nanodroplets. Because of the higher oxygen capacity and longer (1)O2 lifetime of perfluorocarbon, the photodynamic effect of the loaded photosensitizer is significantly enhanced, as demonstrated by the accelerated generation of (1)O2 and elevated cytotoxicity. Following direct injection into tumours, in vivo studies reveal tumour growth inhibition in the Oxy-PDT-treated mice. In addition, a single-dose intravenous injection of Oxy-PDT into tumour-bearing mice significantly inhibits tumour growth, whereas traditional PDT has no effect. Oxy-PDT may enable the enhancement of existing clinical PDT and future PDT design.
Related Papers
- → Photodynamic Therapy (PDT): PDT Mechanisms(2013)657 cited
- → Photodynamic Therapy for Cancer(2006)17 cited
- → The Past and Present of Photodynamic Therapy in Ophthalmology(2021)1 cited
- → 5-aminolevulinic acid (ALA)-mediated photodynamic therapy for superficial skin tumors using Super Lizer(2007)
- Advances of 5-aminolevulinic Acid Photodynamic Therapy in Dermatology and Venerology(2008)